BRPI0814688A2 - composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica - Google Patents
composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêuticaInfo
- Publication number
- BRPI0814688A2 BRPI0814688A2 BRPI0814688A BRPI0814688A BRPI0814688A2 BR PI0814688 A2 BRPI0814688 A2 BR PI0814688A2 BR PI0814688 A BRPI0814688 A BR PI0814688A BR PI0814688 A BRPI0814688 A BR PI0814688A BR PI0814688 A2 BRPI0814688 A2 BR PI0814688A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- warm
- producing
- methods
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94853907P | 2007-07-09 | 2007-07-09 | |
| PCT/GB2008/050548 WO2009007750A1 (en) | 2007-07-09 | 2008-07-08 | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814688A2 true BRPI0814688A2 (pt) | 2017-06-06 |
Family
ID=39791229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814688A BRPI0814688A2 (pt) | 2007-07-09 | 2008-07-08 | composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8138183B2 (en:Method) |
| EP (1) | EP2176238B1 (en:Method) |
| JP (1) | JP5508260B2 (en:Method) |
| KR (1) | KR20100042280A (en:Method) |
| CN (1) | CN101809002B (en:Method) |
| AR (1) | AR070079A1 (en:Method) |
| AT (1) | ATE554075T1 (en:Method) |
| AU (1) | AU2008273891B2 (en:Method) |
| BR (1) | BRPI0814688A2 (en:Method) |
| CA (1) | CA2692720A1 (en:Method) |
| CL (1) | CL2008003940A1 (en:Method) |
| CO (1) | CO6251364A2 (en:Method) |
| CR (1) | CR11200A (en:Method) |
| DO (1) | DOP2010000012A (en:Method) |
| EA (1) | EA018708B1 (en:Method) |
| EC (1) | ECSP109935A (en:Method) |
| ES (1) | ES2385692T3 (en:Method) |
| NI (1) | NI201000002A (en:Method) |
| PE (1) | PE20100138A1 (en:Method) |
| WO (1) | WO2009007750A1 (en:Method) |
| ZA (1) | ZA200909224B (en:Method) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007748A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| CA2755061A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | Pyrimidine derivatives as mtor inhibitors |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| KR20120106714A (ko) | 2009-07-02 | 2012-09-26 | 사노피 | 신규 (6-옥소-1,6-디히드로-피리미딘-2-일)아미드 유도체, 그의 제조법, 및 ａｋｔ(ｐｋｂ) 인산화 억제제로서의 그의 제약 용도 |
| EP2448932B1 (fr) | 2009-07-02 | 2014-03-05 | Sanofi | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4-(3h)-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| US20120316137A1 (en) | 2009-10-30 | 2012-12-13 | Ariad Pharmaceuticals, Inc. | Methods and Compositions for Treating Cancer |
| JP6114554B2 (ja) | 2010-02-03 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定 |
| ES2535116T3 (es) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Derivados de urea sustituida con morfolino como inhibidores de mtor |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| EP2658844B1 (fr) | 2010-12-28 | 2016-10-26 | Sanofi | Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| JP2014510122A (ja) | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体 |
| EA201790045A1 (ru) | 2011-04-29 | 2017-09-29 | Селекта Байосайенсиз, Инк. | Наноносители, вырабатывающие имунную толерантность, для антиген-специфического удаления т-эффекторных клеток |
| AU2012290056B2 (en) | 2011-08-03 | 2015-03-19 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for LKB1 status |
| CA2849189A1 (en) | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| BR112014008241A2 (pt) | 2011-10-07 | 2017-04-18 | Cellzome Ltd | composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto |
| RU2684595C2 (ru) | 2012-07-04 | 2019-04-09 | Ф.Хоффманн-Ля Рош Аг | Ковалентно связанные конъюгаты антиген-антитело |
| FR2994572B1 (fr) * | 2012-08-17 | 2015-04-17 | Centre Nat Rech Scient | Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| JP6417338B2 (ja) * | 2013-02-19 | 2018-11-07 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| EP2986319A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| JP6382949B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法 |
| HK1221150A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪类对癌症的治疗 |
| SG11201508223YA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| EP3549940A1 (en) | 2013-04-17 | 2019-10-09 | Signal Pharmaceuticals, LLC | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| WO2014172431A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| EP2991631A4 (en) | 2013-05-03 | 2016-11-16 | Selecta Biosciences Inc | TOLEROGENIC SYNTHETIC NANOTRANS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR IMPROVED PHARMACODYNAMIC EFFECTS |
| US9604939B2 (en) | 2013-05-29 | 2017-03-28 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EP3164419B1 (en) | 2014-06-26 | 2024-07-24 | F. Hoffmann-La Roche AG | Anti-brdu antibodies and methods of use |
| RS63190B1 (sr) | 2014-08-04 | 2022-06-30 | Nuevolution As | Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti |
| BR112017001311A2 (pt) | 2014-09-07 | 2017-11-14 | Selecta Biosciences Inc | métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| MY198676A (en) | 2017-06-22 | 2023-09-15 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| WO2019014618A1 (en) | 2017-07-13 | 2019-01-17 | Board Of Regents, University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| WO2019036641A1 (en) | 2017-08-17 | 2019-02-21 | Board Of Regents, The University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| WO2019178590A1 (en) | 2018-03-16 | 2019-09-19 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of atr kinase |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11685727B2 (en) | 2019-12-20 | 2023-06-27 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
| TW202337494A (zh) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| JP3810017B2 (ja) * | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| JP2004524279A (ja) * | 2000-11-10 | 2004-08-12 | エフ．ホフマン−ラ ロシュ アーゲー | ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用 |
| US7423148B2 (en) | 2002-11-21 | 2008-09-09 | Chiron Corporation | Small molecule PI 3-kinase inhibitors and methods of their use |
| JP2007500241A (ja) | 2003-05-29 | 2007-01-11 | シンタ ファーマシューティカルズ コーポレーション | 過度の骨量減少に関連する疾患の予防及び治療用の複素環化合物 |
| GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7696202B2 (en) * | 2004-11-10 | 2010-04-13 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006124662A1 (en) | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| NZ563774A (en) | 2005-05-20 | 2010-04-30 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
| DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
| AU2006265840B2 (en) | 2005-07-01 | 2010-02-11 | Irm Llc | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
| WO2007013691A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
| KR20080052630A (ko) * | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Ｒａｆ 억제제 화합물 및 그의 사용 방법 |
| JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
| JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AU2006297351A1 (en) | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| BRPI0616630B8 (pt) | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| TW200800963A (en) | 2005-10-28 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| CA2636314A1 (en) | 2005-11-29 | 2007-06-07 | Toray Industries, Inc. | Arylmethylene urea derivative and use thereof |
| GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| BRPI0706395A2 (pt) * | 2006-01-11 | 2011-03-22 | Astrazeneca Ab | composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8440663B2 (en) | 2006-01-30 | 2013-05-14 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use |
| CN101438288A (zh) | 2006-03-15 | 2009-05-20 | Csir公司 | 谷氨酰胺合成酶的磷酰基转移酶活性的调节 |
| JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
| WO2007114323A1 (ja) | 2006-04-04 | 2007-10-11 | Taisho Pharmaceutical Co., Ltd. | アミノピロリジン化合物 |
| CN101472915A (zh) | 2006-04-19 | 2009-07-01 | 诺瓦提斯公司 | 吲唑化合物和抑制cdc7的方法 |
| JP5225076B2 (ja) | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
| GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
| CA2656290A1 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| WO2008023159A1 (en) * | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| US20090325957A1 (en) * | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| US20080234262A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| US20100256143A1 (en) | 2007-04-12 | 2010-10-07 | Stewart James Baker | Pharmaceutical compounds |
| AU2008273892A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
-
2008
- 2008-07-08 BR BRPI0814688A patent/BRPI0814688A2/pt not_active IP Right Cessation
- 2008-07-08 AT AT08776183T patent/ATE554075T1/de active
- 2008-07-08 US US12/668,056 patent/US8138183B2/en not_active Expired - Fee Related
- 2008-07-08 CN CN2008801062258A patent/CN101809002B/zh not_active Expired - Fee Related
- 2008-07-08 JP JP2010515602A patent/JP5508260B2/ja not_active Expired - Fee Related
- 2008-07-08 KR KR1020107002942A patent/KR20100042280A/ko not_active Ceased
- 2008-07-08 ES ES08776183T patent/ES2385692T3/es active Active
- 2008-07-08 AU AU2008273891A patent/AU2008273891B2/en not_active Ceased
- 2008-07-08 EA EA201000091A patent/EA018708B1/ru not_active IP Right Cessation
- 2008-07-08 EP EP08776183A patent/EP2176238B1/en active Active
- 2008-07-08 CA CA 2692720 patent/CA2692720A1/en not_active Abandoned
- 2008-07-08 WO PCT/GB2008/050548 patent/WO2009007750A1/en not_active Ceased
- 2008-12-19 PE PE2008002157A patent/PE20100138A1/es not_active Application Discontinuation
- 2008-12-30 AR ARP080105784A patent/AR070079A1/es unknown
- 2008-12-30 CL CL2008003940A patent/CL2008003940A1/es unknown
-
2009
- 2009-12-23 ZA ZA2009/09224A patent/ZA200909224B/en unknown
-
2010
- 2010-01-08 DO DO2010000012A patent/DOP2010000012A/es unknown
- 2010-01-08 NI NI201000002A patent/NI201000002A/es unknown
- 2010-01-08 CR CR11200A patent/CR11200A/es not_active Application Discontinuation
- 2010-02-03 EC EC2010009935A patent/ECSP109935A/es unknown
- 2010-02-09 CO CO10014081A patent/CO6251364A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA018708B1 (ru) | 2013-10-30 |
| PE20100138A1 (es) | 2010-03-20 |
| EP2176238B1 (en) | 2012-04-18 |
| DOP2010000012A (es) | 2010-01-31 |
| WO2009007750A1 (en) | 2009-01-15 |
| CN101809002B (zh) | 2013-03-27 |
| CR11200A (es) | 2010-06-17 |
| KR20100042280A (ko) | 2010-04-23 |
| CA2692720A1 (en) | 2009-01-15 |
| AU2008273891A1 (en) | 2009-01-15 |
| ATE554075T1 (de) | 2012-05-15 |
| CL2008003940A1 (es) | 2010-09-24 |
| JP2010533160A (ja) | 2010-10-21 |
| US8138183B2 (en) | 2012-03-20 |
| JP5508260B2 (ja) | 2014-05-28 |
| EP2176238A1 (en) | 2010-04-21 |
| HK1142906A1 (en) | 2010-12-17 |
| EA201000091A1 (ru) | 2010-06-30 |
| AR070079A1 (es) | 2010-03-10 |
| NI201000002A (es) | 2010-10-12 |
| AU2008273891B2 (en) | 2012-01-12 |
| CO6251364A2 (es) | 2011-02-21 |
| ES2385692T3 (es) | 2012-07-30 |
| ZA200909224B (en) | 2011-05-25 |
| ECSP109935A (es) | 2010-03-31 |
| CN101809002A (zh) | 2010-08-18 |
| US20100249131A1 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814688A2 (pt) | composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica | |
| BRPI0814503A2 (pt) | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
| BR122020011920A2 (pt) | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0820474A2 (pt) | método de tratamento de uma doença, uso de composto, e, composto | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0821274A2 (pt) | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
| BRPI0819755A2 (pt) | composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| BRPI0914233A2 (pt) | composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença | |
| BRPI0817917A2 (pt) | Implemento para cuidado oral, e, método para formar um implemento para cuidado oral | |
| BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
| BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
| BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
| BRPI0811275A2 (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |